These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19251903)

  • 1. Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation.
    Robertson EJ; Casadevall A
    Appl Environ Microbiol; 2009 Apr; 75(8):2528-33. PubMed ID: 19251903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.
    Martinez LR; Casadevall A
    Infect Immun; 2005 Oct; 73(10):6350-62. PubMed ID: 16177306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EDTA inhibits biofilm formation, extracellular vesicular secretion, and shedding of the capsular polysaccharide glucuronoxylomannan by Cryptococcus neoformans.
    Robertson EJ; Wolf JM; Casadevall A
    Appl Environ Microbiol; 2012 Nov; 78(22):7977-84. PubMed ID: 22941091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
    Martinez LR; Moussai D; Casadevall A
    Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced phagocytosis and killing of Cryptococcus neoformans biofilm-derived cells by J774.16 macrophages is associated with fungal capsular production and surface modification.
    Lee HH; Del Pozzo J; Salamanca SA; Hernandez H; Martinez LR
    Fungal Genet Biol; 2019 Nov; 132():103258. PubMed ID: 31356873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.
    Feldmesser M; Casadevall A
    Front Biosci; 1998 Feb; 3():d136-51. PubMed ID: 9445465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light.
    Martinez LR; Casadevall A
    Appl Environ Microbiol; 2007 Jul; 73(14):4592-601. PubMed ID: 17513597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
    Duro RM; Netski D; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
    McFadden DC; Casadevall A
    J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties.
    Cordero RJ; Pontes B; Frases S; Nakouzi AS; Nimrichter L; Rodrigues ML; Viana NB; Casadevall A
    J Immunol; 2013 Jan; 190(1):317-23. PubMed ID: 23233725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capsular polysaccharides of Cryptococcus neoformans.
    Bhattacharjee AK; Bennett JE; Glaudemans CP
    Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recognition of intact cells from Cryptococcus neoformans by the anti-glucuronoxylomannan 4B3 monoclonal antibody].
    Gato Armas R; Martínez Machín G; Rodríguez Sánchez H; Otero González A; Sarracent Pérez J; Illnait Zaragozi MT
    Rev Cubana Med Trop; 2006; 58(2):159-61. PubMed ID: 23427436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro.
    Martinez LR; Christaki E; Casadevall A
    J Infect Dis; 2006 Jul; 194(2):261-6. PubMed ID: 16779734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
    Todaro-Luck F; White EH; Reiss E; Cherniak R
    Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biofilm Formation by Cryptococcus neoformans.
    Martinez LR; Casadevall A
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-guided alpha radiation effectively damages fungal biofilms.
    Martinez LR; Bryan RA; Apostolidis C; Morgenstern A; Casadevall A; Dadachova E
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2132-6. PubMed ID: 16723575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells.
    Vecchiarelli A; Pietrella D; Bistoni F; Kozel TR; Casadevall A
    Immunology; 2002 Jun; 106(2):267-72. PubMed ID: 12047756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy.
    Goldman DL; Casadevall A; Zuckier LS
    J Med Vet Mycol; 1997; 35(4):271-8. PubMed ID: 9292424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disarming Fungal Pathogens:
    Mayer FL; Kronstad JW
    mBio; 2017 Oct; 8(5):. PubMed ID: 28974618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.